Home Cart Sign in  
Chemical Structure| 143443-90-7 Chemical Structure| 143443-90-7

Structure of Ifetroban
CAS No.: 143443-90-7

Chemical Structure| 143443-90-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Ifetroban is a long-acting thromboxane A2 receptor antagonist, with antiplatelet activity.

Synonyms: BMS-180291

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Ifetroban

CAS No. :143443-90-7
Formula : C25H32N2O5
M.W : 440.53
SMILES Code : O=C(O)CCC1=CC=CC=C1C[C@H]2[C@](O3)([H])CC[C@]3([H])[C@H]2C4=NC(C(NCCCCC)=O)=CO4
Synonyms :
BMS-180291

Safety of Ifetroban

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Ifetroban

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02216357 - Completed - -
NCT03340675 Duchenne Muscular Dystrophy Ca... More >>rdiomyopathy Cardiomyopathy, Dilated Less << Phase 2 Not yet recruiting December 2021 -
NCT02802228 Portal Hypertension ... More >> Liver Cirrhosis Less << Phase 2 Completed - United States, Florida ... More >> Tampa General Medical Group Tampa, Florida, United States, 33606 United States, Indiana Indiana University Indianapolis, Indiana, United States, 46202 United States, Ohio The Ohio State University Wexner Medical Center Columbus, Ohio, United States, 43210 United States, South Carolina Medical University of South Carolina Charleston, South Carolina, United States, 29425 United States, Texas Baylor University Medical Center Dallas, Texas, United States, 75246 United States, Virginia Virginia Commonwealth University Medical Center Richmond, Virginia, United States, 23114 Less <<
NCT03694249 Anatomic Stage II Breast Cance... More >>r Anatomic Stage IIA Breast Cancer Anatomic Stage IIB Breast Cancer Anatomic Stage III Breast Cancer Anatomic Stage IIIA Breast Cancer Anatomic Stage IIIB Breast Cancer Anatomic Stage IIIC Breast Cancer Clinical Stage II Esophageal Adenocarcinoma Clinical Stage II Esophageal Squamous Cell Carcinoma Clinical Stage II Gastric Cancer Clinical Stage II Gastroesophageal Junction Adenocarcinoma Clinical Stage IIA Esophageal Adenocarcinoma Clinical Stage IIA Gastric Cancer Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma Clinical Stage IIB Esophageal Adenocarcinoma Clinical Stage IIB Gastric Cancer Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma Clinical Stage III Esophageal Adenocarcinoma Clinical Stage III Esophageal Squamous Cell Carcinoma Clinical Stage III Gastric Cancer Clinical Stage III Gastroesophageal Junction Adenocarcinoma Distal Esophagus Squamous Cell Carcinoma Esophageal Carcinoma Estrogen Receptor Negative HER2/Neu Negative Limited Stage Small Cell Lung Carcinoma Malignant Solid Neoplasm Non-Small Cell Lung Carcinoma Pancreatic Adenocarcinoma Pathologic Stage II Esophageal Adenocarcinoma Pathologic Stage II Esophageal Squamous Cell Carcinoma Pathologic Stage II Gastric Cancer Pathologic Stage II Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIA Esophageal Adenocarcinoma Pathologic Stage IIA Esophageal Squamous Cell Carcinoma Pathologic Stage IIA Gastric Cancer Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIB Esophageal Adenocarcinoma Pathologic Stage IIB Esophageal Squamous Cell Carcinoma Pathologic Stage IIB Gastric Cancer Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma Pathologic Stage III Esophageal Adenocarcinoma Pathologic Stage III Esophageal Squamous Cell Carcinoma Pathologic Stage III Gastric Cancer Pathologic Stage III Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIA Esophageal Adenocarcinoma Pathologic Stage IIIA Esophageal Squamous Cell Carcinoma Pathologic Stage IIIA Gastric Cancer Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIB Esophageal Adenocarcinoma Pathologic Stage IIIB Esophageal Squamous Cell Carcinoma Pathologic Stage IIIB Gastric Cancer Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma Pathologic Stage IIIC Gastric Cancer Postneoadjuvant Therapy Stage II Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage II Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage II Gastric Cancer Postneoadjuvant Therapy Stage II Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage III Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage III Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage III Gastric Cancer Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage IIIA Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage IIIA Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma Postneoadjuvant Therapy Stage IIIB Esophageal Adenocarcinoma Postneoadjuvant Therapy Stage IIIB Esophageal Squamous Cell Carcinoma Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma Progesterone Receptor Negative Prognostic Stage II Breast Cancer Prognostic Stage IIA Breast Cancer Prognostic Stage IIB Breast Cancer Prognostic Stage III Breast Cancer Prognostic Stage IIIA Breast Cancer Prognostic Stage IIIB Breast Cancer Prognostic Stage IIIC Breast Cancer Stage I Pancreatic Cancer Stage IA Pancreatic Cancer Stage IB Pancreatic Cancer Stage II Lung Cancer Stage II Pancreatic Cancer Stage IIA Lung Cancer Stage IIA Pancreatic Cancer Stage IIB Lung Cancer Stage IIB Pancreatic Cancer Stage III Lung Cancer Stage IIIA Lung Cancer Stage IIIB Lung Cancer Stage IIIC Lung Cancer Triple-Negative Breast Carcinoma Less << Phase 2 Not yet recruiting January 2023 United States, Tennessee ... More >> Vanderbilt-Ingram Cancer Center Not yet recruiting Nashville, Tennessee, United States, 37232 Contact: Vanderbilt-Ingram Service for Timely Access    800-811-8480    cip@vanderbilt.edu    Principal Investigator: Ingrid Mayer, MD Less <<
NCT01436500 Hepatorenal Syndrome Phase 2 Completed - United States, Arizona ... More >> Mayo Clinic - Arizona Phoenix, Arizona, United States, 85054 United States, California UCSD, Hillcrest Medical Center Hospital La Jolla, California, United States, 92093 UCSF (University of California-San Francisco) San Francisco, California, United States, 94143 United States, Georgia Emory University Hospital Atlanta, Georgia, United States, 30322 United States, Indiana Indiana University (Division of Gastroenterology/Hepatology) Indianapolis, Indiana, United States, 46202 United States, Michigan University of Michigan Hospital Ann Arbor, Michigan, United States, 48109 United States, New York NYU Langone Medical Center New York, New York, United States, 10016 United States, Ohio The Ohio State University Columbus, Ohio, United States, 43210 United States, Texas Baylor All Saints Medical Center Fort Worth, Texas, United States, 76104 United States, Utah University of Utah Health Sciences Center Salt Lake City, Utah, United States, 84132 United States, Virginia Virginia Commonwealth University Richmond, Virginia, United States, 23298 India MIDAS Multispeciality Hospital PVT LTD Nagpur, Maharashtra, India, 440010 Less <<
NCT02216357 Aspirin Exacerbated Respirator... More >>y Disease (AERD) Less << Phase 2 Completed - United States, California ... More >> Scripps Clinic San Diego, California, United States, 32130 United States, Kansas Kansas City Allergy and Asthma Associates, PA. Overland Park, Kansas, United States, 66210 United States, New York Allergy & Asthma Consultants of Rockland & Bergen West Nyack, New York, United States, 10994 Less <<
NCT03326063 Nasal Polyps ... More >>Asthma, Aspirin-Induced Aspirin-exacerbated Respiratory Disease Aspirin-Sensitive Asthma With Nasal Polyps Less << Phase 2 Recruiting February 2021 United States, Massachusetts ... More >> Asthma Research Center, Brigham and Women's Hospital Recruiting Boston, Massachusetts, United States, 02115 Contact: Meghan Le    617-732-8201    mle8@bwh.harvard.edu Less <<
NCT02682511 Scleroderma, Diffuse ... More >> Scleroderma, Systemic Scleroderma, Limited Sclerosis, Progressive Systemic Skin Diseases Connective Tissue Diseases Pathologic Processes Autoimmune Diseases Less << Phase 2 Recruiting February 2020 United States, California ... More >> UCLA Recruiting Los Angeles, California, United States, 90095-1670 Contact: Nashla Barroso    310-825-9682       Principal Investigator: Suzanne Kafaja, MD          United States, Florida New Life Medical Research Center, Inc. Recruiting Hialeah, Florida, United States, 33012 Contact: Barbara Diaz, BS    786-360-3750    diaz@newlifemedresearch.com    Principal Investigator: Odalys P Frontela, MD          United States, Maryland Johns Hopkins University Recruiting Baltimore, Maryland, United States, 21224 Contact: Gwen Leatherman, RN, MS, CCRP    410-550-8582       Principal Investigator: Laura Hummer, MD          United States, Massachusetts Massachusetts General Hospital Recruiting Boston, Massachusetts, United States, 02114 Contact: Kaitlin Schalago    617-724-2792       Contact: Ana Fernandez    617-724-2792       Principal Investigator: Flavia Castelino, MD          United States, New York Hospital for Special Surgery Recruiting New York, New York, United States, 10021 Contact: Alexandra Morquette    212-774-7194       Principal Investigator: Jessica Gordon, MD          United States, South Carolina Medical University of South Carolina Recruiting Charleston, South Carolina, United States, 29403 Contact: Kelley Kajdasz    843-792-5290       Principal Investigator: Richard Silver, MD          United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37203 Contact: Rezzan Hekmat, MHS    615-875-8937       Principal Investigator: Evan Brittain, MD Less <<
NCT03028350 Asthma, Aspirin-Induced Phase 2 Recruiting December 2019 United States, California ... More >> Scripps Clinic - Carmel Valley Recruiting San Diego, California, United States, 92130 Contact: Nancy Giovanetty    858-764-3023       Principal Investigator: Andrew White, MD          Stanford University Medical Center Recruiting Stanford, California, United States, 94305 Contact: Aakanksha Rathor, MD    408-872-2257       Principal Investigator: Peter Hwang, MD          United States, Florida The Research Center Recruiting Hialeah, Florida, United States, 33013 Contact: Laine Batista    305-603-8844       Contact: Damian Beltran-Garces    (305) 603-8844       United States, Kansas Kansas City Allergy and Asthma Associates, PA Recruiting Overland Park, Kansas, United States, 66210 Contact: James B Sterner, MD    913-338-1610       Contact: Andrea Bennington, CCRC    913-338-1610       United States, New York Montefiore Medical Center Recruiting Bronx, New York, United States, 10461 Contact: Mydalyn Beronilla, MPH    929-263-3262       Principal Investigator: Elina Jerschow, MD          United States, Ohio Clinical Research Trials , LLC Recruiting Canton, Ohio, United States, 44718 Contact: Nashat Gabrail, MD    330-492-3345       Contact: Hannah Crocker    330-492-3345       United States, Pennsylvania University of Pennsylvania Recruiting Philadelphia, Pennsylvania, United States, 19104 Contact: John V Bosso, MD          Contact: Laurel Doghramji, BSN    215-615-1643       United States, Tennessee Vanderbilt University Medical Center Recruiting Nashville, Tennessee, United States, 37232 Contact: Cindy Dorminy, MEd, LPN    615-936-8384       Principal Investigator: Rakesh Chandra, MD          United States, Texas UT Southwestern Medical Center Recruiting Dallas, Texas, United States, 75390-9035 Contact: Mary Martin    214-648-3626       Principal Investigator: David Khan, MD          United States, Virginia University of Virginia Medical Center Recruiting Charlottesville, Virginia, United States, 22908 Contact: B.J. Ferrebee Ghamandi, MHA    434-243-1558       Principal Investigator: Spencer Payne, MD Less <<
NCT01436500 - Completed - -

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.35mL

2.27mL

1.13mL

22.70mL

4.54mL

2.27mL

 

Historical Records

Categories